Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Middleton

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
The Lancet. Oncology|May 26, 2022
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control studyLennard Y W Lee, Thomas Starkey, Maria C Ionescu, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2022
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based studyLennard Y W Lee, Maria C Ionescu, Thomas Starkey, et al.
JAMA Oncology|December 22, 2022
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional EvaluationLennard Y W Lee, Michael Tilby, Thomas Starkey, et al.
Scientific Reports|July 25, 2023
A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)Thomas Starkey, Maria C Ionescu, Michael Tilby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Nature Genetics|September 11, 2012
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagusZhan Su, Laura J Gay, Amy Strange, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
The Lancet. Oncology|May 26, 2022
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control studyLennard Y W Lee, Thomas Starkey, Maria C Ionescu, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2022
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based studyLennard Y W Lee, Maria C Ionescu, Thomas Starkey, et al.
JAMA Oncology|December 22, 2022
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional EvaluationLennard Y W Lee, Michael Tilby, Thomas Starkey, et al.
Scientific Reports|July 25, 2023
A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)Thomas Starkey, Maria C Ionescu, Michael Tilby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Nature Genetics|September 11, 2012
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagusZhan Su, Laura J Gay, Amy Strange, et al.
Pageof 6